Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist

Cancer Research

Volumn 67, Issue 13, 2007, Pages 6012-6016

  Giubellino, Alessio ^a   Gao, Yang ^a   Lee, Sunmin ^a   Lee, Min Jung ^a   Vasselli, James R ^a   Medepalli, Sampath ^a   Trepel, Jane B ^a   Burke Jr , Terrence R ^b   Bottaro, Donald P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETASTATIC AGENT; C90 PROTEIN; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2 SRC HOMOLOGY 2 DOMAIN BINDING ANTAGONIST; PROTEIN SH2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL MOTILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; MALE; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; SOLID TUMOR; TUMOR GROWTH; TUMOR MODEL;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GRB2 ADAPTOR PROTEIN; HUMANS; MICE; MICE, SCID; MICROSCOPY, FLUORESCENCE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; TETRAZOLIUM SALTS; THIAZOLES;

EID: 34447132249     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0022     Document Type: Article

References (18)

1. Christofori G. New signals from the invasive front. Nature 2006;441:444-50.
2. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127:679-95.
3. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006;12:895-904.
4. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003;3:453-8.
5. McLean GW, Carragher NO, Avizienyte E, et al. The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer 2005;5:505-15.
6. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-25.
7. Christensen JG, Burrows J, Salgia R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Letters 2005;225:1-26.
8. Corso S, Comoglio PM, Giordano S. Cancer therapy: can the challenge be MET? Trends Mol Med 2005;11:284-92.
9. Yaffe MB. Phosphotyrosine-binding domains in signal transduction. Nat Rev Mol Cell Biol 2002;3:177-86.
10. Dharmawardana PG, Peruzzi B, Giubellino A, et al. Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy. Anticancer Drugs 2006;17:13-20.
11. Atabey N, Gao Y, Yao ZJ, et al. Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions. J Biol Chem 2001;276:14308-14.
12. Soriano JV, Liu N, Gao Y, et al. Inhibition of angiogenesis by growth factor receptor bound protein 2-Src homology 2 domain bound antagonists. Mol Cancer Ther 2004;3:1289-99.
13. Day RM, Soon L, Breckenridge D, et al. Mitogenic synergy through multilevel convergence of hepatocyte growth factor and interleukin-4 signaling pathways. Oncogene 2002;21:2201-11.
14. Zhang YW, Vande Woude GF. HGF/SF-met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 2003;88:408-17.
15. Kozlowski JM, Fidler IJ, Campbell D, et al. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res 1984;44:3522-9.
16. Suyama K, Shapiro I, Guttman M, Hazan RB. A signaling pathway leading to metastasis is controlled by N-cadherin and the FGF receptor. Cancer Cell 2002;2:301-14.
17. Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote survival and migration of melanoma cells. Cancer Res 2001;61:3819-25.
18. Fidler IJ. Critical determinants of metastasis. Semin Cancer Biol 2002;12:89-96.